ACHIEVE-1 Study Shows Albuferon Non-Inferior To Pegasys; Questions Remain
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With the March 9 release of the initial results of ACHIEVE-1, the final Phase III trial of Human Genome Sciences/Novartis' pegylated interferon Albuferon, Wall Street analysts have started to question the hepatitis C drug's market value. The trial failed to deliver outstanding efficacy results, and showed some signs of safety problems